Despite evolving infrastructure for alternative cosmetic testing in China, the regulatory climate remains hazy, according to L’Oreal SA, which recently obtained a license to market Episkin reconstructed skin models in the country for testing substances without the use of animals.
Animal-Test Alternatives Progress In China Despite Regulatory Uncertainty
China took steps earlier this year to begin phasing out required animal-testing for selected cosmetic products; however, the Chinese government has yet to approve any alternative assessment methods. Nonprofit organizations and leading firms such as L’Oreal are focused on helping stakeholders to incorporate in vitro test methods internally and develop their scientific and technical know-how as the regulatory picture crystallizes.
More from Archive
More from HBW Insight
• By
The departure data emerged along with a Health and Human Services Department memo describing conceptual plans to consolidate and restructure offices at the FDA and other agencies.
• By
Fragrance Creators Association will push the Trump Administration to exclude from tariffs fragrance materials that cannot be produced or cultivated domestically, while both FCA and the Personal Care Products Council will continue to promote the economic benefits of their respective industries.
• By
Agreement with Seoul-based health and wellness player TopHealth will see the roll out of ProBiotix' cholesterol-lowering probiotics in South Korea.